Catalent remains persistent with its internal restructuring initiative: Lays Off 130 Employees at Indiana Facility

In the face of a multi-billion-dollar acquisition offer from Novo Holdings, the contract manufacturer Catalent remains persistent with its internal restructuring initiative unveiled last year.

Moreover, the company is also contemplating workforce adjustments. This shall affect over a hundred employees at its manufacturing and filling facility in Bloomington, Indiana. The reports show approximately 130 impending staff reductions at the mentioned site.

These anticipated layoffs represent a distinct initiative from the prior workforce reduction campaign conducted between October and December 2023. As a result, approximately 300 people were laid off by the company. The spokesperson emphasized the company’s commitment to long-term sustainable growth and underscored Catalent's ongoing efforts to enhance its operational efficiencies and streamline the costs across its operations.

Specific details regarding the affected roles and the timeline for implementation have yet to be disclosed. 

Despite Catalent's progression toward a potential $16.5 billion acquisition by Novo Holdings, many former employees will not be retained under the new ownership structure.

Catalent's restructuring strategy, initially introduced last year, has culminated in recent layoffs totaling around 300 employees between October and December 2023, as revealed in the company's quarterly filing.

The restructuring efforts initiated by Catalent last summer, which included cost reductions and facility consolidations, have expanded to encompass layoffs across its biologics, pharmaceuticals, and consumer health segments. The decision to close the San Francisco facility, announced in October, is a direct outcome of these restructuring measures, contributing to the latest layoffs.